ArticleDiscover oncology2025
TCF19 expression and significance analysis in breast cancer: integrated bioinformatics analysis and histological validation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging Role of Transcription Factor 19 (TCF19) in Inflammatory Disease and Cancer.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTranscription factor 19 (TCF19) is an important member of the transcription factor family, but its role in cancer is not well understood. This study aims to clarify the function of TCF19 and explore its mechanisms across various cancers, with a specific focus on breast cancer, using bioinformatics analysis and histological validation.
methodsGene expression profiles and clinical data were obtained from sources like The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Genotype-Tissue Expression (GTEx) for bioinformatics analysis. Tumor-immune interactions were studied using the TISIDB database for immune-related insights. To confirm these findings, TCF19 expression was measured using quantitative RT-PCR, immunohistochemistry (IHC), and western blot assays. Additional validation was done with various experimental techniques, including CCK-8, colony-forming, transwell, and cell line-derived xenograft assays.
resultsTCF19 is significantly upregulated in many cancerous tissues, including breast cancer, as confirmed across multiple datasets and clinical samples. Higher TCF19 levels were associated with a poorer prognosis. Experimentally reducing TCF19 expression in MCF-7 cells impaired key cellular functions such as proliferation, invasion, migration, and tumor formation. Pathway enrichment analysis of TCGA samples revealed a strong link between TCF19 and the PLK1 pathway, a finding further supported by western blot results showing PLK1 downregulation following TCF19 silencing.
conclusionsHigh TCF19 expression is closely linked to poorer outcomes, especially in breast cancer. These findings highlight TCF19 as a promising biomarker with broad potential applications in cancer diagnosis and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.